A very small study of six patients in China has given sufferers of hepatocellular carcinoma hope that a new treatment could be on the horizon, Endpoints News reports.
This most common form of liver cancer has proven difficult to tackle, but good results were seen in half of these patients, for whom other treatments have failed. After treatment with the experimental chimeric antigen receptor (CAR) T-cell treatment (Eureka Therapeutics), two saw their tumours shrink, while one patient was tumour free after the treatment, and remained so at the seven-month check-up.
MAP will watch with interest the development of CAR-T treatments around the world, as they have great potential to bring relief to patents of several conditions. MAP have followed the stories of Kymriah and Yescarta as they have progressed from trial to HTA body, and will continue to monitor the field.